

## Bial

[View the current Bial Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/19332-Bial.html) (<http://www.bioportfolio.com/biocorporate/19332-Bial.html>)

### Contact Details:

Tel: 351 22 986 6100

Fax: 351 22 986 6190

Email: [info@bial.com](mailto:info@bial.com)

In a time characterised by globalisation, the international dimension of Bial is playing an ever greater role in the group's strategic objectives. Being part of the global market and responding to the needs of the people in an ever larger number of world regions is an essential part of Bial's commitment to Society.

Bial is today an International Pharmaceutical Group. Our products are to be found in pharmacies in nearly 30 countries in 4 continents: Europe, America, Africa and Asia. Whether in Spain or in the Dominican Republic, Portugal or Mozambique, Cyprus, Senegal or Ecuador, the members of the Bial Group and its representatives always strive to serve and satisfy health professionals and the general public. Some of the group companies are: Laboratórios Bial, Medibial, Bialfar, Bialport, Bial Aristegui, Medimport and Medangol.

### Recent Publications by Bial:



- [Effect of questionnaire structure on recall of drug utilization in a population of university students.](#)  
*BACKGROUND: Self-reported data are a common source of information about...* 11th November, 2009  
Department of Hygiene and Epidemiology, University of Porto Medical- BMC Med Res Methodol. 2009 Jun 29;9:45. ([DOI Direct Link](#))
- [Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.](#)  
*Eslicarbazepine acetate (ESL) is a new-generation voltage-gated sodium...* 31st October, 2009  
Department of Research and Development, BIAL - Portela & Co, SA, S Mamede- Fundam Clin Pharmacol. 2009 Aug;23(4):509-14. Epub 2009 Jun 4. ([DOI Direct Link](#))
- [Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy.](#)  
*BACKGROUND: Specifically designed recombinant allergens with reduced IgE...* 31st October, 2009  
Bial-Aristegui, Research & Development Department, Bilbao, Spain.- Clin Exp Allergy. 2009 Jul;39(7):1088-98. Epub 2009 Apr 21. ([DOI Direct Link](#))
- [Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone.](#)  
*The present study was designed to characterize pharmacodynamic and...* 20th October, 2009  
Department of Research and Development, BIAL, 4745-457 S. Mamede do- Biochem Pharmacol. 2009 Oct 15;78(8):1043-51. Epub 2009 Jun 6. ([DOI Direct Link](#))

- [Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.](#)  
*This was a double-blind, randomised, placebo-controlled study to...* 28th August, 2009  
 Department of Research and Development, BIAL-Portela & Co SA, S Mamede do- Mol Nutr Food Res. 2009 May;53 Suppl 1:S7-15. ([DOI Direct Link](#))
- [Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects.](#)  
*PURPOSE: Eslicarbazepine acetate (ESL) is a new voltage-gated sodium...* 3rd June, 2009  
 Department of Research and Development, BIAL, S. Mamede do Coronado,- Int J Clin Pharmacol Ther. 2009 Apr;47(4):255-61.
- [Recombinant hypoallergens for immunotherapy of Parietaria judaica pollen allergy.](#)  
*Recombinant allergens are a promising alternative to crude allergen...* 8th April, 2009  
 Bial-Artegui, Research and Development Department, Alameda Urquijo, 27,- Front Biosci. 2009 Jan 1;14:4606-17.
- [Adverse non-drug-related complaints by healthy volunteers in Phase I studies compared to the healthy general population.](#)  
*OBJECTIVE: Some complaints that are reported as adverse drug reactions by...* 16th January, 2009  
 Department of Research and Development, BIAL-Portela, SA, S. Mamede do- Int J Clin Pharmacol Ther. 2008 Nov;46(11):574-83.
- [Effect of food on the pharmacokinetic profile of trans-resveratrol.](#)  
*OBJECTIVE: It has been postulated that trans-resveratrol may act as an...* 16th January, 2009  
 Department of Research and Development, BIAL, S. Mamede do Coronado,- Int J Clin Pharmacol Ther. 2008 Nov;46(11):564-70.
- [Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.](#)  
*OBJECTIVE: Nebicapone is a new catechol-O-methyltransferase inhibitor. In...* 17th December, 2008  
 Department of Research & Development, BIAL, S Mamede do Coronado,- Eur J Clin Pharmacol. 2008 Oct;64(10):961-6. Epub 2008 Aug 6. ([DOI Direct Link](#))
- [Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.](#)  
*This study investigates the pharmacokinetics of eslicarbazepine acetate...* 4th November, 2008  
 Department of Research and Development, BIAL, A Av. da Siderurgia- J Clin Pharmacol. 2008 Aug;48(8):966-77. Epub 2008 May 28. ([DOI Direct Link](#))
- [Personality characteristics of volunteers in Phase 1 studies and likelihood of reporting adverse events.](#)  
*OBJECTIVE: To evaluate the personality characteristics of a group of...* 8th October, 2008  
 Department of Research and Development, BIAL (Portela and Co., SA), S.- Int J Clin Pharmacol Ther. 2008 Jul;46(7):340-8.
- [Efficient synthesis of 2-\(trifluoromethyl\)nicotinic acid derivatives from simple fluorinated precursors.](#)  
*Novel routes to 2-trifluoromethyl-nicotinic acid derivatives have been...* 8th August, 2008  
 BIAL-Portela and Ca, Trofa, Portugal.- Org Lett. 2008 May 1;10(9):1835-7. Epub 2008 Apr 10. ([DOI Direct Link](#))
- [Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate.](#)  
*OBJECTIVE: Antiepileptic drugs are often used in patients with some degree...* 5th June, 2008  
 Department of Research and Development, BIAL (Portela & Ca SA), S. Mamede- Int J Clin Pharmacol Ther. 2008 Mar;46(3):119-30.

## Press Releases on Bial:

[Novel Once Daily Anti-Epileptic Zebinix\(R\) Approved in the European Union](#)

28th April, 2009

S.MAMEDE DO  
CORONADO, Portugal and  
LONDON, April 28  
/PRNewswire/ -- Bial-Portela  
& CA, S.A., (S. Mamede do  
Coronado, Portugal,  
President & CEO Dr Luis  
Portela), and Eisai Europe  
Limited

[Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix\(R\)](#)

19th February, 2009

LONDON, February 19  
/PRNewswire/ -- Eisai Europe  
Ltd (London; Chairman &  
CEO Yutaka Tsuchiya), the  
European subsidiary of Eisai  
Co., Ltd. (Tokyo, President &  
CEO: Haruo Naito), and Bial

#### Bial Clinical Trials:



- [Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

